FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2285143471> ?p ?o ?g. }

• W2285143471 endingPage "303" @default.
• W2285143471 startingPage "297" @default.
• W2285143471 abstract "Purpose To evaluate the effectiveness of definitive or adjuvant external beam proton therapy on survival in patients with chordomas and chondrosarcomas of the spine. Methods and Materials Between March 2007 and May 2013, 51 patients with a median age of 58 years (range, 22-83 years) with chordoma (n=34) or chondrosarcomas (n=17) of the sacrum (n=21), the cervical spine (n=20), and the thoracolumbar spine (n=10) were treated with external beam proton therapy to a median dose of 70.2 Gy(RBE) [range, 64.2-75.6 Gy(RBE)] at our institution. Distant metastases, overall survival, cause-specific survival, local control, and disease-free survival were calculated. Results The mean follow-up time was 3.7 years (range, 0.3-7.7 years). Across all time points, 25 patients experienced disease recurrence: 18 local recurrences, 6 local and distant recurrences, and 1 distant metastasis. The 4-year rates of overall survival and cause-specific survival were 72%; disease-free survival was 57%, local control was 58%, and freedom from distant metastases was 86%. The median time to local progression was 1.7 years (range, 0.2-6.0 years), and the median time to distant progression was 1.6 years (range, 0.2-6.0 years). The risk factors for local recurrence were age ≤58 years (62% vs 26%; P=.04) and recurrence after prior surgery (29% vs 81%; P=.01). Secondary cancers developed in 2 patients: B-cell lymphoma 5.5 years after treatment and bladder cancer 2 years after treatment. We observed the following toxicities: sacral soft tissue necrosis requiring surgery (n=2), T1 vertebral fracture requiring fusion surgery (n=1), chronic urinary tract infections (n=1), surgery for necrotic bone cyst (n=1), and grade 2 bilateral radiation nephritis (n=1). Conclusion High-dose proton therapy controls more than half of spinal chordomas and chondrosarcomas and compares favorably with historic photon data. Local progression is the dominant mode of treatment failure and may be reduced by treating patients at the time of initial diagnosis. The impact of age is a novel finding of this study. To evaluate the effectiveness of definitive or adjuvant external beam proton therapy on survival in patients with chordomas and chondrosarcomas of the spine. Between March 2007 and May 2013, 51 patients with a median age of 58 years (range, 22-83 years) with chordoma (n=34) or chondrosarcomas (n=17) of the sacrum (n=21), the cervical spine (n=20), and the thoracolumbar spine (n=10) were treated with external beam proton therapy to a median dose of 70.2 Gy(RBE) [range, 64.2-75.6 Gy(RBE)] at our institution. Distant metastases, overall survival, cause-specific survival, local control, and disease-free survival were calculated. The mean follow-up time was 3.7 years (range, 0.3-7.7 years). Across all time points, 25 patients experienced disease recurrence: 18 local recurrences, 6 local and distant recurrences, and 1 distant metastasis. The 4-year rates of overall survival and cause-specific survival were 72%; disease-free survival was 57%, local control was 58%, and freedom from distant metastases was 86%. The median time to local progression was 1.7 years (range, 0.2-6.0 years), and the median time to distant progression was 1.6 years (range, 0.2-6.0 years). The risk factors for local recurrence were age ≤58 years (62% vs 26%; P=.04) and recurrence after prior surgery (29% vs 81%; P=.01). Secondary cancers developed in 2 patients: B-cell lymphoma 5.5 years after treatment and bladder cancer 2 years after treatment. We observed the following toxicities: sacral soft tissue necrosis requiring surgery (n=2), T1 vertebral fracture requiring fusion surgery (n=1), chronic urinary tract infections (n=1), surgery for necrotic bone cyst (n=1), and grade 2 bilateral radiation nephritis (n=1). High-dose proton therapy controls more than half of spinal chordomas and chondrosarcomas and compares favorably with historic photon data. Local progression is the dominant mode of treatment failure and may be reduced by treating patients at the time of initial diagnosis. The impact of age is a novel finding of this study." @default.
• W2285143471 created "2016-06-24" @default.
• W2285143471 creator A5008642709 @default.
• W2285143471 creator A5009854212 @default.
• W2285143471 creator A5015258714 @default.
• W2285143471 creator A5023899503 @default.
• W2285143471 creator A5024806569 @default.
• W2285143471 creator A5026252270 @default.
• W2285143471 creator A5059111895 @default.
• W2285143471 date "2016-05-01" @default.
• W2285143471 modified "2023-10-16" @default.
• W2285143471 title "A Prospective Outcomes Study of Proton Therapy for Chordomas and Chondrosarcomas of the Spine" @default.
• W2285143471 cites W1563804318 @default.
• W2285143471 cites W1786224258 @default.
• W2285143471 cites W1909155065 @default.
• W2285143471 cites W1971742491 @default.
• W2285143471 cites W1984301456 @default.
• W2285143471 cites W1990232437 @default.
• W2285143471 cites W1993882008 @default.
• W2285143471 cites W2003161432 @default.
• W2285143471 cites W2016264742 @default.
• W2285143471 cites W2017710644 @default.
• W2285143471 cites W2023845399 @default.
• W2285143471 cites W2039564677 @default.
• W2285143471 cites W2066225048 @default.
• W2285143471 cites W2073461770 @default.
• W2285143471 cites W2074078368 @default.
• W2285143471 cites W2090459018 @default.
• W2285143471 cites W2092818017 @default.
• W2285143471 cites W2101270354 @default.
• W2285143471 cites W2108649822 @default.
• W2285143471 cites W2120155459 @default.
• W2285143471 cites W2131701437 @default.
• W2285143471 cites W2131712508 @default.
• W2285143471 cites W2164835172 @default.
• W2285143471 cites W2313494909 @default.
• W2285143471 cites W2328386299 @default.
• W2285143471 cites W4230945060 @default.
• W2285143471 cites W4239537730 @default.
• W2285143471 cites W56208417 @default.
• W2285143471 doi "https://doi.org/10.1016/j.ijrobp.2016.01.057" @default.
• W2285143471 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27084648" @default.
• W2285143471 hasPublicationYear "2016" @default.
• W2285143471 type Work @default.
• W2285143471 sameAs 2285143471 @default.
• W2285143471 citedByCount "82" @default.
• W2285143471 countsByYear W22851434712016 @default.
• W2285143471 countsByYear W22851434712017 @default.
• W2285143471 countsByYear W22851434712018 @default.
• W2285143471 countsByYear W22851434712019 @default.
• W2285143471 countsByYear W22851434712020 @default.
• W2285143471 countsByYear W22851434712021 @default.
• W2285143471 countsByYear W22851434712022 @default.
• W2285143471 countsByYear W22851434712023 @default.
• W2285143471 crossrefType "journal-article" @default.
• W2285143471 hasAuthorship W2285143471A5008642709 @default.
• W2285143471 hasAuthorship W2285143471A5009854212 @default.
• W2285143471 hasAuthorship W2285143471A5015258714 @default.
• W2285143471 hasAuthorship W2285143471A5023899503 @default.
• W2285143471 hasAuthorship W2285143471A5024806569 @default.
• W2285143471 hasAuthorship W2285143471A5026252270 @default.
• W2285143471 hasAuthorship W2285143471A5059111895 @default.
• W2285143471 hasConcept C141071460 @default.
• W2285143471 hasConcept C2776302905 @default.
• W2285143471 hasConcept C2779244869 @default.
• W2285143471 hasConcept C2780739268 @default.
• W2285143471 hasConcept C2781190729 @default.
• W2285143471 hasConcept C3019894029 @default.
• W2285143471 hasConcept C509974204 @default.
• W2285143471 hasConcept C71924100 @default.
• W2285143471 hasConceptScore W2285143471C141071460 @default.
• W2285143471 hasConceptScore W2285143471C2776302905 @default.
• W2285143471 hasConceptScore W2285143471C2779244869 @default.
• W2285143471 hasConceptScore W2285143471C2780739268 @default.
• W2285143471 hasConceptScore W2285143471C2781190729 @default.
• W2285143471 hasConceptScore W2285143471C3019894029 @default.
• W2285143471 hasConceptScore W2285143471C509974204 @default.
• W2285143471 hasConceptScore W2285143471C71924100 @default.
• W2285143471 hasIssue "1" @default.
• W2285143471 hasLocation W22851434711 @default.
• W2285143471 hasLocation W22851434712 @default.
• W2285143471 hasOpenAccess W2285143471 @default.
• W2285143471 hasPrimaryLocation W22851434711 @default.
• W2285143471 hasRelatedWork W1971658951 @default.
• W2285143471 hasRelatedWork W1981576515 @default.
• W2285143471 hasRelatedWork W2059224910 @default.
• W2285143471 hasRelatedWork W2090095394 @default.
• W2285143471 hasRelatedWork W2339538311 @default.
• W2285143471 hasRelatedWork W2527127071 @default.
• W2285143471 hasRelatedWork W3031519187 @default.
• W2285143471 hasRelatedWork W3172831092 @default.
• W2285143471 hasRelatedWork W3216891713 @default.
• W2285143471 hasRelatedWork W4307146663 @default.
• W2285143471 hasVolume "95" @default.
• W2285143471 isParatext "false" @default.
• W2285143471 isRetracted "false" @default.
• W2285143471 magId "2285143471" @default.
• W2285143471 workType "article" @default.